trending Market Intelligence /marketintelligence/en/news-insights/trending/jWrJuLsN8jH8MrZiV_3KbQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

United Therapeutics gets updated US label for hypertension drug Orenitram

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

United Therapeutics gets updated US label for hypertension drug Orenitram

United Therapeutics Corp. said the U.S. Food and Drug Administration approved the inclusion of new data from a late-stage study to the label of hypertension drug Orenitram.

The updated label will indicate that Orenitram, or treprostinil, in extended-release tablets delays disease worsening when used with an approved oral background therapy for pulmonary arterial hypertension, the Silver Spring, Md.-based company said.

Patients with pulmonary arterial hypertension experience high blood pressure in the blood vessel that carries blood from the heart to the lungs. This can lead to chest pain, fatigue and eventual heart failure.

Results from the study, called Freedom-EV, showed patients treated with Orenitram had a 26% lesser risk of experiencing a clinical worsening event, compared to their placebo-treated counterparts. The company said this was largely driven by delay in disease progression, the risk for which Orenitram cut by 61%, compared to placebo.

The FDA originally approved Orenitram in 2013, with a label indicating that Orenitram, when used as a single therapy, improves the capacity of patients with pulmonary arterial hypertension to exercise.

In the U.S., pulmonary hypertension is more common among women, non-Hispanic blacks, and among people aged 75 or older, according to the Centers for Disease Control and Prevention.